PCRX
Pacira BioSciences, Inc.
Key Financials
Operating Income
$19.2M
↑ 126.2%
Revenue
$726.4M
↑ 3.6%
EPS (Diluted)
$0.16
↑ 107.4%
Total Assets
$1.3B
↓ 18.6%
Shareholders' Equity
$693.1M
↓ 11.0%
Net Income
$7.0M
↑ 107.1%
Long-term Debt
$372.2M
↓ 36.4%
Total Liabilities
$571.8M
↓ 26.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 3 | 6/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PCRX |
| Company Name | Pacira BioSciences, Inc. |
| CIK | 1396814 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-242-8052 |